Clinical trial participants with principal pathological health anxiety (n = 335) and a sample of healthy volunteers (n = 88) completed the 14-item Whiteley Index (WI-14), the Illness Attitude Scale (IAS), and the 14-, 18-, and 64-item Health Anxiety Inventory (the HAI-64, HAI-18, and HAI-14). Cross-sectional data from all participants were pooled (N = 423) and we conducted a joint factor analysis and approximate equipercentile linking of the WI-14, IAS, HAI-64, HAI-18, and HAI-14.
Inter-scale correlations were high (rs ≥ 0.90 and ≥ 0.88 in adjusted analyses), and the scree plot of the joint factor analysis spoke for a unifactorial solution where 89/105 items (85%) had loadings ≥ 0.40. Most items at the core of this broad trait health anxiety factor pertained to the worry about health, the fear of having or developing a serious disease, and to some extent bodily preoccupation. We present a cross-walk table of observed equipercentile linked sum scores.
This study speaks clearly in favor of the WI-14, IAS, HAI-64, HAI-18, and HAI-14 all tapping into the same trait health anxiety construct, the core of which appears to concern the worry about health, the fear of having or developing a serious disease, and to some extent bodily preoccupation. Based on recently reported cut-offs for the HAI-14, a reasonable cutoff for pathological health anxiety in a psychiatric setting probably lies around 7-8 on the WI-14, 52-53 on the IAS, 82-83 on the HAI-64, and 26-27 on the HAI-18.
ClinicalTrials.gov NCT01966705, NCT02314065.
方法:具有主要病理性健康焦虑(n=335)和健康志愿者样本(n=88)的临床试验参与者完成了14项Whiteley指数(WI-14),疾病态度量表(IAS),和14-,18-,和64项健康焦虑量表(HAI-64、HAI-18和HAI-14)。来自所有参与者的横截面数据被汇总(N=423),我们进行了联合因子分析和WI-14,IAS,HAI-64、HAI-18和HAI-14。
结果:量表间相关性很高(校正分析中rs≥0.90和≥0.88),联合因子分析的scree图说明了89/105项目(85%)的载荷≥0.40的单因子解决方案。这种广泛的特质健康焦虑因素的核心大多数项目都与对健康的担忧有关,对患有或发展为严重疾病的恐惧,在某种程度上,身体上的注意力。我们提供了一个观察到的等百分位数链接总和分数的交叉走表。
结论:这项研究清楚地表明支持WI-14,IAS,HAI-64,HAI-18和HAI-14都使用相同的特质健康焦虑结构,其核心似乎涉及对健康的担忧,对患有或发展为严重疾病的恐惧,在某种程度上,身体上的注意力。根据最近报道的HAI-14的截止日期,在精神病学背景下,病理健康焦虑的合理截止日期可能在WI-14的7-8,IAS的52-53左右,82-83在HAI-64上,26-27在HAI-18上。
背景:ClinicalTrials.govNCT01966705,NCT02314065。